Genewity
Private Company
Funding information not available
Overview
Genewity is a private, clinical-stage biotech focused on pioneering stem cell-based gene therapies for rare pediatric diseases. Its lead program targets RAG1-SCID, with early clinical results showing restored immune function. The company leverages a patient-centric, autologous ex vivo approach where a patient's own bone marrow stem cells are genetically modified and reinfused, aiming for durable, one-time cures. Based in the Leiden Bio Science Park, Genewity is building a pipeline of therapies for severe genetic disorders with high unmet need.
Technology Platform
Autologous ex vivo stem cell gene therapy platform using patient's own bone marrow stem cells, genetically modified to insert a functional gene copy, then reinfused for durable, one-time treatment.
Opportunities
Risk Factors
Competitive Landscape
Genewity competes in the growing field of gene therapy for rare diseases, facing competition from both large pharma (e.g., Novartis, BioMarin) and biotech peers (e.g., Orchard Therapeutics, Rocket Pharma). Its specific focus on ex vivo HSC gene therapy for pediatric immunodeficiencies places it in direct competition with companies developing similar approaches for SCID and other disorders.